Dinaciclib, a CDK5 inhibitor, is in a preclinical trial for the treatment of multiple types of cancer [61], including liver cancer [62], thyroid cancer [63], and chronic lymphocytic leukemia [64]. The gene discussed is CDK5; the disease is B-cell chronic lymphocytic leukemia.